Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Jazz to Acquire Rights to Defibrotide from Sigma-Tau

July 2, 2014 3:50 pm | News | Comments

Jazz Pharmaceuticals plc announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals Inc. under which a subsidiary of Jazz Pharmaceuticals plc will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Read more...


Coming Soon: A Harder-to-Abuse Zohydro

July 2, 2014 3:43 pm | News | Comments

The drugmaker Zogenix said a harder-to-abuse version of its powerful painkiller Zohydro could be reviewed by regulators this fall and, if approved, might hit the market early next year, and they are also working to develop a tablet version that maintains the medicine's extended-release properties even when it is crushed or chewed. Read more...


BI Submits MAAs in Europe for COPD Combo Drug

July 2, 2014 3:34 pm | News | Comments

Boehringer Ingelheim announced the submission of Marketing Authorization Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol Respimat as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease. Read more...


Actavis Acquires Furiex Pharmaceuticals

July 2, 2014 3:28 pm | News | Comments

Actavis announced that its subsidiary Forest Laboratories has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. Read more...


Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Articles | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...


“Extensive” Errors Prompt Retraction of Stem Cell Claim

July 2, 2014 3:06 pm | by Malcolm Ritter, AP Science Writer | News | Comments

Scientists who reported that they'd found a startlingly simple way to make stem cells withdrew that claim Wednesday, admitting to "extensive" errors in the research that meant "we are unable to say without a doubt" that the method works. Read more...


New Reprogramming Method Makes Better Stem Cells

July 2, 2014 1:07 pm | News | Comments

A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells. Read more...


RNA Reprogramming Technology for Generates Virus-free iPSCs

July 2, 2014 1:03 pm | EMD Millipore | Product Releases | Comments

Simplicon RNA Reprogramming Technology from EMD Millipore uses synthetic self-replicating RNA to create large numbers of human induced pluripotent stem cells (iPSCs) using a single transfection step. Read more...


Safe, Efficient Concentration of Biological Samples

July 2, 2014 11:04 am | Product Releases | Comments

The miVac DNA is a compact concentrator from Genevac capable of safely and efficiently removing water and organic solvents from biological samples in a variety of formats including tubes, microplates and vials. Read more...


Pfizer Receives Kosher Certification for Gaucher Disease Drug

July 2, 2014 10:55 am | News | Comments

Pfizer Inc. announced that the Orthodox Union has granted kosher certification to Elelyso (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. Read more...


Isis Earns $1M from GSK for Advancing Hep B Program

July 2, 2014 10:49 am | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus, a serious health problem that can lead to significant and potentially fatal health conditions. Read more...


Common Element of Ancient Origin Controls Na, Ca Cellular Gates

July 2, 2014 10:43 am | News | Comments

Researchers at Johns Hopkins have spotted a strong family trait in two distant relatives: The channels that permit entry of sodium and calcium ions into cells - both of which are critical to life - turn out to share similar means for regulating ion intake, they say. Read more...


Lung Cancer Alliance Commends NCI for SCLC Scientific Framework

July 2, 2014 10:32 am | News | Comments

The National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. Read more...


Roche Buying Seragon for Up to $1.7B

July 2, 2014 10:13 am | News | Comments

Roche Holding AG - the Basel, Switzerland-based pharmaceutical giant - said its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals Inc. for up to $1.725 billion in cash and contingency payments. Read more...


OncoGenex Opens Enrollment for Lung Cancer Trial

July 2, 2014 8:30 am | News | Comments

OncoGenex announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Read more...      



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.